Form 4: Nurix Therapeutics Director Paul M. Silva Acquires 25,000 Stock Options

Director Paul M. Silva acquired 25,000 stock options in Nurix Therapeutics, Inc. on May 19, 2025, vesting fully by May 19, 2026, or the next annual meeting.

Summary

• On May 19, 2025, Paul M. Silva, a director of Nurix Therapeutics, Inc., acquired 25,000 stock options.
• The exercise price of these options is $9.51.
• The options vest 100% on the earlier of the next annual meeting of Nurix Therapeutics' stockholders or May 19, 2026, contingent upon Silva's continued service to the company.
• The options expire on May 18, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a director. It indicates confidence but doesn't provide substantial positive or negative information.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the stock options is contingent upon the director's continued service to the company, aligning his interests with those of the shareholders.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment, as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, Nurix Therapeutics, director, Form 4, NRIX, insider trading